Ken Griffin Bio Line Rx Ltd. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 75,100 shares of BLRX stock, worth $229,806. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75,100
Previous 46,500
61.51%
Holding current value
$229,806
Previous $25,000
36.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding BLRX
# of Institutions
36Shares Held
2.83MCall Options Held
75.1KPut Options Held
5.1K-
Highbridge Capital Management LLC New York, NY1.01MShares$3.09 Million0.05% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.5 Million4.05% of portfolio
-
Values First Advisors, Inc.166KShares$509,3330.02% of portfolio
-
Atria Wealth Solutions, Inc. New York, NY94.1KShares$288,0460.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC92KShares$281,5200.0% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $188M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...